Use of a new drug in the treatment of infectious complications after minimally invasive surgery for urolithiasis

Authors:
Publisher website
Google Scholar
Abstract
The aim of the study was to evaluate the efficacy of fluorothiazinone in a real-world clinical setting. Material and methods. The paper presents the initial results of clinical application of combination therapy for infectious and inflammatory complications following endourological surgeries using the new antibacterial drug fluorothiazinone in a urology department. Clinical and laboratory data were analyzed, and the results of microbiological examination methods were examined. Results. Analysis of body temperature dynamics revealed a significant decrease in temperature in the fluorothiazinone group, with the average body temperature on day 3 being closer to normal than in the control group. Clinical improvement was observed in 92.3 % of patients on day 3 of therapy, compared to 37 % in the control group. In the fluorothiazinone group, stable positive dynamics in reducing inflammatory markers were observed on day 3 of therapy. Fluorothiazinone has been demonstrated to be effective in suppressing biofilm formation, and significant cytotoxicity suppression of clinical isolates of K. pneumoniae has been demonstrated in vitro. Conclusion: Given the multidrug resistance of hospital-acquired strains, timely initiation of antibacterial therapy based on local microbiological monitoring in combination with the new drug fluorothiazinone has proven effective in treating this complex group of patients.

This publication has 9 references indexed in Scilit: